This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

adalimumab (Humira®)

Reference No. 8

Publication date:

Appraisal information

adalimumab (Humira®) 40 mg solution for injection

Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 21/02/2012
AWMSG meeting date: 21/03/2012
Submission Type: Limited Submission
Status: Superseded
Advice No: 0812
Ratification by Welsh Government: 25/04/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) in combination with methotrexate is recommended as an option for use within NHS Wales for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab (Humira®) can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. AWMSG is of the opinion that adalimumab (Humira®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary